COHEN & STEERS INC (CNS) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:CNS - US19247A1007 - Common Stock
66.11 USD
-0.44 (-0.66%)
66.11 USD
0 (0%)
CNS gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 235 industry peers in the Capital Markets industry. CNS has an excellent profitability rating, but there are some minor concerns on its financial health. While showing a medium growth rate, CNS is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
CNS had positive earnings in the past year.
CNS had a negative operating cash flow in the past year.
Each year in the past 5 years CNS has been profitable.
Each year in the past 5 years CNS had a positive operating cash flow.
1.2 Ratios
The Return On Assets of CNS (20.48%) is better than 97.87% of its industry peers.
The Return On Equity of CNS (29.83%) is better than 95.74% of its industry peers.
Looking at the Return On Invested Capital, with a value of 24.24%, CNS belongs to the top of the industry, outperforming 98.30% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for CNS is significantly above the industry average of 7.14%.
The last Return On Invested Capital (24.24%) for CNS is well below the 3 year average (28.30%), which needs to be investigated, but indicates that CNS had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.48% | ||
| ROE | 29.83% | ||
| ROIC | 24.24% |
ROA(3y)20.51%
ROA(5y)25.29%
ROE(3y)38.03%
ROE(5y)48.18%
ROIC(3y)28.3%
ROIC(5y)38.19%
1.3 Margins
Looking at the Profit Margin, with a value of 29.73%, CNS is in the better half of the industry, outperforming 76.17% of the companies in the same industry.
In the last couple of years the Profit Margin of CNS has declined.
With a decent Operating Margin value of 33.83%, CNS is doing good in the industry, outperforming 65.53% of the companies in the same industry.
CNS's Operating Margin has declined in the last couple of years.
With an excellent Gross Margin value of 88.60%, CNS belongs to the best of the industry, outperforming 93.19% of the companies in the same industry.
In the last couple of years the Gross Margin of CNS has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.83% | ||
| PM (TTM) | 29.73% | ||
| GM | 88.6% |
OM growth 3Y-9.18%
OM growth 5Y-3.03%
PM growth 3Y-6.88%
PM growth 5Y-2.25%
GM growth 3Y0.74%
GM growth 5Y0.55%
2. Health
2.1 Basic Checks
CNS has more shares outstanding than it did 1 year ago.
CNS has more shares outstanding than it did 5 years ago.
CNS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 9.25 indicates that CNS is not in any danger for bankruptcy at the moment.
The Altman-Z score of CNS (9.25) is better than 94.89% of its industry peers.
CNS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 9.25 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
CNS has a Current Ratio of 0.79. This is a bad value and indicates that CNS is not financially healthy enough and could expect problems in meeting its short term obligations.
CNS has a worse Current ratio (0.79) than 63.83% of its industry peers.
CNS has a Quick Ratio of 0.79. This is a bad value and indicates that CNS is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of CNS (0.79) is worse than 63.40% of its industry peers.
CNS does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.79 | ||
| Quick Ratio | 0.79 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 8.87% over the past year.
Measured over the past 5 years, CNS shows a small growth in Earnings Per Share. The EPS has been growing by 2.50% on average per year.
The Revenue has grown by 11.13% in the past year. This is quite good.
The Revenue has been growing slightly by 4.72% on average over the past years.
EPS 1Y (TTM)8.87%
EPS 3Y-10.08%
EPS 5Y2.5%
EPS Q2Q%5.19%
Revenue 1Y (TTM)11.13%
Revenue growth 3Y-3.95%
Revenue growth 5Y4.72%
Sales Q2Q%6.39%
3.2 Future
The Earnings Per Share is expected to grow by 7.68% on average over the next years.
Based on estimates for the next years, CNS will show a small growth in Revenue. The Revenue will grow by 7.21% on average per year.
EPS Next Y4.56%
EPS Next 2Y8.37%
EPS Next 3Y8.1%
EPS Next 5Y7.68%
Revenue Next Year7.42%
Revenue Next 2Y8.4%
Revenue Next 3Y7.58%
Revenue Next 5Y7.21%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 21.53 indicates a rather expensive valuation of CNS.
CNS's Price/Earnings ratio is in line with the industry average.
Compared to an average S&P500 Price/Earnings ratio of 26.92, CNS is valued a bit cheaper.
CNS is valuated rather expensively with a Price/Forward Earnings ratio of 19.21.
CNS's Price/Forward Earnings ratio is in line with the industry average.
When comparing the Price/Forward Earnings ratio of CNS to the average of the S&P500 Index (23.57), we can say CNS is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.53 | ||
| Fwd PE | 19.21 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CNS is valued a bit cheaper than 78.30% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 16.51 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
CNS has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)4.72
PEG (5Y)8.62
EPS Next 2Y8.37%
EPS Next 3Y8.1%
5. Dividend
5.1 Amount
CNS has a Yearly Dividend Yield of 3.95%. Purely for dividend investing, there may be better candidates out there.
Compared to an average industry Dividend Yield of 6.39, CNS has a dividend in line with its industry peers.
Compared to an average S&P500 Dividend Yield of 1.94, CNS pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.95% |
5.2 History
The dividend of CNS decreases each year by -7.12%.
CNS has been paying a dividend for at least 10 years, so it has a reliable track record.
CNS has decreased its dividend in the last 3 years.
Dividend Growth(5Y)-7.12%
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
CNS pays out 76.25% of its income as dividend. This is not a sustainable payout ratio.
DP76.25%
EPS Next 2Y8.37%
EPS Next 3Y8.1%
66.11
-0.44 (-0.66%)
Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)
Earnings (Next)
Inst Owners58.73%
Inst Owner Change0%
Ins Owners22.81%
Ins Owner Change3.25%
Market Cap3.37B
Revenue(TTM)552.10M
Net Income(TTM)164.16M
Analysts48
Price Target78.54 (18.8%)
Short Float %6.31%
Short Ratio4
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.95% |
Yearly Dividend2.39
Dividend Growth(5Y)-7.12%
DP76.25%
Div Incr Years2
Div Non Decr Years2
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.39%
Min EPS beat(2)-4.27%
Max EPS beat(2)3.48%
EPS beat(4)1
Avg EPS beat(4)-0.86%
Min EPS beat(4)-4.27%
Max EPS beat(4)3.48%
EPS beat(8)3
Avg EPS beat(8)-0.49%
EPS beat(12)5
Avg EPS beat(12)0.41%
EPS beat(16)9
Avg EPS beat(16)1.94%
Revenue beat(2)1
Avg Revenue beat(2)-0.16%
Min Revenue beat(2)-1.18%
Max Revenue beat(2)0.85%
Revenue beat(4)2
Avg Revenue beat(4)-2.44%
Min Revenue beat(4)-11.33%
Max Revenue beat(4)1.91%
Revenue beat(8)3
Avg Revenue beat(8)-1.39%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.35%
PT rev (3m)-1.28%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.13%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.87%
Revenue NQ rev (1m)-0.14%
Revenue NQ rev (3m)2.7%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)0.24%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.53 | ||
| Fwd PE | 19.21 | ||
| P/S | 6.11 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 6.13 | ||
| P/tB | 6.36 | ||
| EV/EBITDA | 16.51 |
EPS(TTM)3.07
EY4.64%
EPS(NY)3.44
Fwd EY5.2%
FCF(TTM)-1.84
FCFYN/A
OCF(TTM)-1.7
OCFYN/A
SpS10.82
BVpS10.79
TBVpS10.39
PEG (NY)4.72
PEG (5Y)8.62
Graham Number27.3
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.48% | ||
| ROE | 29.83% | ||
| ROCE | 31.59% | ||
| ROIC | 24.24% | ||
| ROICexc | 29.06% | ||
| ROICexgc | 32.58% | ||
| OM | 33.83% | ||
| PM (TTM) | 29.73% | ||
| GM | 88.6% | ||
| FCFM | N/A |
ROA(3y)20.51%
ROA(5y)25.29%
ROE(3y)38.03%
ROE(5y)48.18%
ROIC(3y)28.3%
ROIC(5y)38.19%
ROICexc(3y)52.58%
ROICexc(5y)66.96%
ROICexgc(3y)63.61%
ROICexgc(5y)82.87%
ROCE(3y)36.88%
ROCE(5y)49.77%
ROICexgc growth 3Y-36.94%
ROICexgc growth 5Y-14.2%
ROICexc growth 3Y-34.4%
ROICexc growth 5Y-13.57%
OM growth 3Y-9.18%
OM growth 5Y-3.03%
PM growth 3Y-6.88%
PM growth 5Y-2.25%
GM growth 3Y0.74%
GM growth 5Y0.55%
F-Score5
Asset Turnover0.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 63.99% | ||
| Cap/Sales | 1.34% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.79 | ||
| Quick Ratio | 0.79 | ||
| Altman-Z | 9.25 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)429.54%
Cap/Depr(5y)277.84%
Cap/Sales(3y)4.88%
Cap/Sales(5y)3.14%
Profit Quality(3y)59.63%
Profit Quality(5y)81.14%
High Growth Momentum
Growth
EPS 1Y (TTM)8.87%
EPS 3Y-10.08%
EPS 5Y2.5%
EPS Q2Q%5.19%
EPS Next Y4.56%
EPS Next 2Y8.37%
EPS Next 3Y8.1%
EPS Next 5Y7.68%
Revenue 1Y (TTM)11.13%
Revenue growth 3Y-3.95%
Revenue growth 5Y4.72%
Sales Q2Q%6.39%
Revenue Next Year7.42%
Revenue Next 2Y8.4%
Revenue Next 3Y7.58%
Revenue Next 5Y7.21%
EBIT growth 1Y15.71%
EBIT growth 3Y-12.76%
EBIT growth 5Y1.55%
EBIT Next Year11.2%
EBIT Next 3Y14.28%
EBIT Next 5Y13.32%
FCF growth 1Y-175.84%
FCF growth 3Y-29.26%
FCF growth 5Y-9.31%
OCF growth 1Y-150.56%
OCF growth 3Y-26.44%
OCF growth 5Y-7.32%
COHEN & STEERS INC / CNS FAQ
What is the ChartMill fundamental rating of COHEN & STEERS INC (CNS) stock?
ChartMill assigns a fundamental rating of 6 / 10 to CNS.
What is the valuation status for CNS stock?
ChartMill assigns a valuation rating of 3 / 10 to COHEN & STEERS INC (CNS). This can be considered as Overvalued.
Can you provide the profitability details for COHEN & STEERS INC?
COHEN & STEERS INC (CNS) has a profitability rating of 8 / 10.
Can you provide the financial health for CNS stock?
The financial health rating of COHEN & STEERS INC (CNS) is 6 / 10.
What is the expected EPS growth for COHEN & STEERS INC (CNS) stock?
The Earnings per Share (EPS) of COHEN & STEERS INC (CNS) is expected to grow by 4.56% in the next year.